Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Thursday 05 May, 2016

GlaxoSmithKline PLC

Result of AGM

RNS Number : 4291X
GlaxoSmithKline PLC
05 May 2016
 

GlaxoSmithKline plc

 

 Result of AGM

 

GlaxoSmithKline plc ('GSK') announces that at its Annual General Meeting ('AGM') today, all resolutions were passed by shareholders. The full text of each resolution is contained in the 2016 Notice of AGM, which is available on the GSK website, www.gsk.com

 

GSK AGM Poll Results

 

The following table shows the total number of votes cast for each resolution:

 

Resolution

Total votes for*

%

Total votes against

%

Total votes cast

Votes withheld**

1

To receive the 2015 Annual Report

3,669,218,924

99.05

35,061,988

0.95

3,704,280,912

5,261,084

2

Approval of the Annual Remuneration Report

2,540,987,583

84.66

460,527,692

15.34

3,001,515,275

708,024,810

3

Election of Vindi Banga

3,685,603,989

99.46

20,087,621

0.54

3,705,691,610

3,847,903

4

Election of Dr Jesse Goodman

3,700,820,176

99.86

5,098,265

0.14

3,705,918,441

3,621,220

5

Re-election of Sir Philip Hampton

3,678,982,107

99.28

26,862,132

0.72

3,705,844,239

3,698,027

6

Re-election of Sir Andrew Witty

3,683,792,948

99.40

22,182,401

0.60

3,705,975,349

3,569,171

7

Re-election of Professor Sir Roy Anderson

3,613,878,165

97.52

92,011,809

2.48

3,705,889,974

3,648,285

8

Re-election of Stacey Cartwright

3,614,959,774

97.55

90,964,624

2.45

3,705,924,398

3,615,316

9

Re-election of Simon Dingemans

3,546,542,373

95.70

159,260,080

4.30

3,705,802,453

3,739,812

10

Re-election of Lynn Elsenhans

3,689,867,659

99.57

16,065,159

0.43

3,705,932,818

3,606,897

11

Re-election of Judy Lewent

3,603,842,229

97.24

102,181,719

2.76

3,706,023,948

3,513,813

12

Re-election of Urs Rohner

3,592,628,299

96.95

113,209,089

3.05

3,705,837,388

3,695,508

13

Re-election of Dr Moncef Slaoui

3,600,056,654

97.14

105,875,118

2.86

3,705,931,772

3,611,731

14

Re-appointment of auditors

3,641,870,505

98.24

65,155,953

1.76

3,707,026,458

2,515,807

15

Remuneration of auditors

3,693,883,936

99.68

12,020,539

0.32

3,705,904,475

3,632,301

16

Authority for the company to make donations to political organisations and incur political expenditure

3,614,540,404

98.19

66,705,675

1.81

3,681,246,079

28,294,561

17

Authority to allot shares

3,557,940,858

96.09

144,791,595

3.91

3,702,732,453

6,808,690

18

Disapplication of pre-emption rights***

3,206,747,187

88.23

427,795,940

11.77

3,634,543,127

74,993,676

19

Authority for the company to purchase its own shares***

3,591,814,300

96.93

113,781,713

3.07

3,705,596,013

3,952,127

20

Exemption from statement of senior statutory auditor's name

3,648,560,466

99.15

31,169,134

0.85

3,679,729,600

29,811,350

21

Authorise reduced notice of a general meeting other than an AGM***

3,223,721,215

87.61

455,747,014

12.39

3,679,468,229

30,073,919

 

Notes:

*

Includes discretionary votes.

**

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

***

Indicates Special Resolutions requiring a 75% majority.

 

The Board notes the votes against and withheld in respect of resolution 2, the approval of the Remuneration Report. The Remuneration Committee will be conducting a review of the Directors' Remuneration Policy during 2016 and will consult and engage with major investors in advance of the vote on the Company's Remuneration Policy Report at our 2017 AGM.

 

Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers did not stand for re-election as Directors, and stepped down from the Board with effect from the conclusion of the AGM.

In accordance with section 430(2B) of the Companies Act 2006, GSK confirms that Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers will receive payment of fees for service whilst a Director but no other remuneration payment or payment for loss of office will be made in connection with their departure.

The following table provides further relevant information:

 


 

GSK's Sixteenth

AGM

(2016)

 

 

GSK's

Fifteenth AGM

(2015)

 

Issued share capital (excluding Treasury Shares)

4,871,555,095

4,866,216,110

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

76.15%

75.30%

Total shareholder population

132,895

137,658

Total number of proxies lodged

8,020

8,686

% of shareholders who lodged proxies

6.03%

6.31%

Number of shareholders, corporate representatives and proxies who attended the AGM

448

403

 

 

V A Whyte

Company Secretary

 

5 May 2016

 

These results will shortly be available on the company's website at www.gsk.com.

 

 

GSK enquiries:

 




UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)


Simon Steel

+44 (0) 20 8047 5502

(London)


Eleanor Craven

+44 (0) 20 8047 5502

(London)


Anna Carruth

+44 (0) 20 8047 5502

(London)





US Media enquiries:

Sarah Alspach

+1 202 715 1048

(Washington, DC)


Sarah Spencer

+1 215 751 3335

(Philadelphia)


Jenni Ligday

+1 202 715 1049

(Washington, DC)





Analyst/Investor enquiries:

Ziba Shamsi

+44 (0) 20 8047 5543

(London)


Tom Curry

+ 1 215 751 5419

(Philadelphia)


Gary Davies

+44 (0) 20 8047 5503

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGAKPDNABKDCPK

a d v e r t i s e m e n t